Unlock new value from existing molecules.
Pharmaceutical companies do not lack molecules. What is often missing is a way to know which biology those molecules actually fit.
Human-first discovery, applied to your portfolio.
We identify new, biologically grounded and potentially protectable indications for existing, shelved, deprioritised, failed or patent-maturing drugs, supported by human genetics, mechanistic evidence, AI and clinical translation.
Shelved and deprioritised assets
Molecules that cleared safety but missed their original endpoint often fit a different mechanism.
Patent-maturing molecules
A new mechanism-led indication can extend the commercial life of an established medicine.
Failed programs
Failure is frequently an indication problem rather than a molecule problem.
Four kinds of conversation.
Pharma
Unlock new value from existing molecules through human-first therapeutic discovery.
New indications for the assets you already own, grounded in human genetics and mechanistic evidence.
Investors
A clinically grounded platform capable of generating multiple therapeutic assets from existing drugs.
The scalability of an AI-enabled discovery platform with the risk-reduction of human genetic evidence, existing medicines and patient validation.
Research and clinical partners
Translate genetic discoveries into therapeutic interventions.
We connect patient genetics, mechanistic biology, AI-enabled drug matching and clinical development.
Patients and clinicians
Finding new answers in medicines that already exist.
We learn from individual patients to uncover the biology of their disease and identify existing medicines that may address its underlying mechanism.